Cargando…

Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case–control study

INTRODUCTION: We aimed to compare intensive care unit mortality due to non-pneumococcal severe community-acquired pneumonia between the periods 2000–2002 and 2008–2014, and the impact of the improvement in antibiotic strategies on outcomes. METHODS: This was a matched case–control study enrolling 14...

Descripción completa

Detalles Bibliográficos
Autores principales: Gattarello, Simone, Lagunes, Leonel, Vidaur, Loreto, Solé-Violán, Jordi, Zaragoza, Rafael, Vallés, Jordi, Torres, Antoni, Sierra, Rafael, Sebastian, Rosa, Rello, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570589/
https://www.ncbi.nlm.nih.gov/pubmed/26369551
http://dx.doi.org/10.1186/s13054-015-1051-1
_version_ 1782390222997159936
author Gattarello, Simone
Lagunes, Leonel
Vidaur, Loreto
Solé-Violán, Jordi
Zaragoza, Rafael
Vallés, Jordi
Torres, Antoni
Sierra, Rafael
Sebastian, Rosa
Rello, Jordi
author_facet Gattarello, Simone
Lagunes, Leonel
Vidaur, Loreto
Solé-Violán, Jordi
Zaragoza, Rafael
Vallés, Jordi
Torres, Antoni
Sierra, Rafael
Sebastian, Rosa
Rello, Jordi
author_sort Gattarello, Simone
collection PubMed
description INTRODUCTION: We aimed to compare intensive care unit mortality due to non-pneumococcal severe community-acquired pneumonia between the periods 2000–2002 and 2008–2014, and the impact of the improvement in antibiotic strategies on outcomes. METHODS: This was a matched case–control study enrolling 144 patients with non-pneumococcal severe pneumonia: 72 patients from the 2000–2002 database (CAPUCI I group) were paired with 72 from the 2008–2014 period (CAPUCI II group), matched by the following variables: microorganism, shock at admission, invasive mechanical ventilation, immunocompromise, chronic obstructive pulmonary disease, and age over 65 years. RESULTS: The most frequent microorganism was methicillin-susceptible Staphylococcus aureus (22.1 %) followed by Legionella pneumophila and Haemophilus influenzae (each 20.7 %); prevalence of shock was 59.7 %, while 73.6 % of patients needed invasive mechanical ventilation. Intensive care unit mortality was significantly lower in the CAPUCI II group (34.7 % versus 16.7 %; odds ratio (OR) 0.78, 95 % confidence interval (CI) 0.64–0.95; p = 0.02). Appropriate therapy according to microorganism was 91.5 % in CAPUCI I and 92.7 % in CAPUCI II, while combined therapy and early antibiotic treatment were significantly higher in CAPUCI II (76.4 versus 90.3 % and 37.5 versus 63.9 %; p < 0.05). In the multivariate analysis, combined antibiotic therapy (OR 0.23, 95 % CI 0.07–0.74) and early antibiotic treatment (OR 0.07, 95 % CI 0.02–0.22) were independently associated with decreased intensive care unit mortality. CONCLUSIONS: In non-pneumococcal severe community-acquired pneumonia , early antibiotic administration and use of combined antibiotic therapy were both associated with increased intensive care unit survival during the study period.
format Online
Article
Text
id pubmed-4570589
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45705892015-09-16 Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case–control study Gattarello, Simone Lagunes, Leonel Vidaur, Loreto Solé-Violán, Jordi Zaragoza, Rafael Vallés, Jordi Torres, Antoni Sierra, Rafael Sebastian, Rosa Rello, Jordi Crit Care Research INTRODUCTION: We aimed to compare intensive care unit mortality due to non-pneumococcal severe community-acquired pneumonia between the periods 2000–2002 and 2008–2014, and the impact of the improvement in antibiotic strategies on outcomes. METHODS: This was a matched case–control study enrolling 144 patients with non-pneumococcal severe pneumonia: 72 patients from the 2000–2002 database (CAPUCI I group) were paired with 72 from the 2008–2014 period (CAPUCI II group), matched by the following variables: microorganism, shock at admission, invasive mechanical ventilation, immunocompromise, chronic obstructive pulmonary disease, and age over 65 years. RESULTS: The most frequent microorganism was methicillin-susceptible Staphylococcus aureus (22.1 %) followed by Legionella pneumophila and Haemophilus influenzae (each 20.7 %); prevalence of shock was 59.7 %, while 73.6 % of patients needed invasive mechanical ventilation. Intensive care unit mortality was significantly lower in the CAPUCI II group (34.7 % versus 16.7 %; odds ratio (OR) 0.78, 95 % confidence interval (CI) 0.64–0.95; p = 0.02). Appropriate therapy according to microorganism was 91.5 % in CAPUCI I and 92.7 % in CAPUCI II, while combined therapy and early antibiotic treatment were significantly higher in CAPUCI II (76.4 versus 90.3 % and 37.5 versus 63.9 %; p < 0.05). In the multivariate analysis, combined antibiotic therapy (OR 0.23, 95 % CI 0.07–0.74) and early antibiotic treatment (OR 0.07, 95 % CI 0.02–0.22) were independently associated with decreased intensive care unit mortality. CONCLUSIONS: In non-pneumococcal severe community-acquired pneumonia , early antibiotic administration and use of combined antibiotic therapy were both associated with increased intensive care unit survival during the study period. BioMed Central 2015-09-10 2015 /pmc/articles/PMC4570589/ /pubmed/26369551 http://dx.doi.org/10.1186/s13054-015-1051-1 Text en © Gattarello et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Gattarello, Simone
Lagunes, Leonel
Vidaur, Loreto
Solé-Violán, Jordi
Zaragoza, Rafael
Vallés, Jordi
Torres, Antoni
Sierra, Rafael
Sebastian, Rosa
Rello, Jordi
Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case–control study
title Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case–control study
title_full Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case–control study
title_fullStr Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case–control study
title_full_unstemmed Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case–control study
title_short Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case–control study
title_sort improvement of antibiotic therapy and icu survival in severe non-pneumococcal community-acquired pneumonia: a matched case–control study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570589/
https://www.ncbi.nlm.nih.gov/pubmed/26369551
http://dx.doi.org/10.1186/s13054-015-1051-1
work_keys_str_mv AT gattarellosimone improvementofantibiotictherapyandicusurvivalinseverenonpneumococcalcommunityacquiredpneumoniaamatchedcasecontrolstudy
AT lagunesleonel improvementofantibiotictherapyandicusurvivalinseverenonpneumococcalcommunityacquiredpneumoniaamatchedcasecontrolstudy
AT vidaurloreto improvementofantibiotictherapyandicusurvivalinseverenonpneumococcalcommunityacquiredpneumoniaamatchedcasecontrolstudy
AT soleviolanjordi improvementofantibiotictherapyandicusurvivalinseverenonpneumococcalcommunityacquiredpneumoniaamatchedcasecontrolstudy
AT zaragozarafael improvementofantibiotictherapyandicusurvivalinseverenonpneumococcalcommunityacquiredpneumoniaamatchedcasecontrolstudy
AT vallesjordi improvementofantibiotictherapyandicusurvivalinseverenonpneumococcalcommunityacquiredpneumoniaamatchedcasecontrolstudy
AT torresantoni improvementofantibiotictherapyandicusurvivalinseverenonpneumococcalcommunityacquiredpneumoniaamatchedcasecontrolstudy
AT sierrarafael improvementofantibiotictherapyandicusurvivalinseverenonpneumococcalcommunityacquiredpneumoniaamatchedcasecontrolstudy
AT sebastianrosa improvementofantibiotictherapyandicusurvivalinseverenonpneumococcalcommunityacquiredpneumoniaamatchedcasecontrolstudy
AT rellojordi improvementofantibiotictherapyandicusurvivalinseverenonpneumococcalcommunityacquiredpneumoniaamatchedcasecontrolstudy